Protalix BioTherapeutics
PLX
23 hedge funds and large institutions have $14.8M invested in Protalix BioTherapeutics in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 10 closing their positions.
10% more call options, than puts
Call options by funds: $378K | Put options by funds: $343K
2.42% less ownership
Funds ownership: 14.68% → 12.26% (-2.4%)
8% less funds holding
Funds holding: 25 → 23 (-2)
20% less capital invested
Capital invested by funds: $18.4M → $14.8M (-$3.6M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$8.85M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$199K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$180K |
| 4 |
Capstone Investment Advisors
New York
|
+$79.4K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$39K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$9.42M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$751K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$605K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$577K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$538K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KCM
26
Kennedy Capital Management
St Louis,
Missouri
| – | -$577K | -149,151 | Closed |
|
|
EMG
27
ETF Managers Group
Summit,
New Jersey
| – | -$397K | -101,768 | Closed |
|
|
MWPCG
28
Measured Wealth Private Client Group
Portsmouth,
New Hampshire
| – | -$148K | -38,116 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | -$64.7K | -18,043 | Closed |
|
30
VanEck Associates
New York
| – | -$35K | -9,096 | Closed |
|
31
BlackRock
New York
| – | -$24K | -6,284 | Closed |
|
PLX Hedge Fund Activity: Q4 2020 in Review
23 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2020, worth a combined $14.8M — down 20% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PLX and 8 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 1 added.
The largest buyer was Burrage Capital Management, opening a new position worth an estimated $8.85M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $9.42M sold.
- 23 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2020, down from 25 in Q3 2020.
- Funds reported $14.8M of Protalix BioTherapeutics stock for Q4 2020, down 20% quarter-over-quarter.
- 8 funds opened new Protalix BioTherapeutics positions in Q4 2020 and 10 closed out, a net change of -2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2020 was Burrage Capital Management, an estimated $8.85M added.
- The largest Protalix BioTherapeutics seller in Q4 2020 was Highbridge Capital Management, an estimated $9.42M sold.
Based on aggregated 13F filings for Q4 2020.